Results 81 to 90 of about 53,199 (230)
Journal of Neuroinflammation, 2018 Background Bortezomib is a frequently used chemotherapeutic drug for the treatment of multiple myeloma and other nonsolid malignancies. Accumulating evidence has demonstrated that bortezomib-induced persistent pain serves as the most frequent reason for ...
Kun Chen +5 more
doaj +1 more source
BV173 treatment with 4nM bortezomib.
, 2022 (A+B): Ph+ cells BV173 were treated with DMSO, dasatinib 50nM, bortezomib 4nM and combination at day 0. Viability was measured every 24h to day 5 using PI staining assay. Dasatinib as well as the combination of dasatinib and bortezomib caused a reduction
Margherita Vieri (3482504) +8 more
core +1 more source
British Journal of Haematology, EarlyView.Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard +2 more
wiley +1 more source
Haematologica, 2012 Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling +11 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà +48 more
wiley +1 more source
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
, 2015 Nishanth Vallumsetla, Jonas Paludo, Prashant Kapoor Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA Abstract: Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma ...
Paludo J, Kapoor P, Vallumsetla N
core
Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
Frontiers in Oncology, 2019 Multiple myeloma (MM) drug resistance highlights a need for alternative therapeutic strategies. In this study, we show that CASIN, a selective inhibitor of cell division cycle 42 (Cdc42) GTPase, inhibited proliferation and survival of melphalan ...
Phuong Nguyen +13 more
doaj +1 more source
, 2019 Ziqi Ye,1,* Jie Chen,2,* Zixue Xuan,3 Wenchao Yang,4 Jing Chen51Department of Pharmacy, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2Department of Pharmacy, the Second ...
Yang W, Chen J, Xuan Z, Ye Z
core
PLoS ONE, 2013 CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we investigated CK2 expression in multiple myeloma and mantle cell lymphoma, two bortezomib ...
Sabrina Manni +16 more
doaj +1 more source
, 2009 Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The first in class proteasome ...
Sheeba K Thomas +2 more
core